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funding from external research.  It is an affiliated research unit of the Faculty of Medicine, 
The University of Sydney.  The centre aims to contribute to the development and application 
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CHERE’s research program encompasses both the theory and application of health 
economics.  The main theoretical research theme pursues valuing benefits, including 
understanding what individuals value from health and health care, how such values should be 
measured, and exploring the social values attached to these benefits.  The applied research 
focuses on economic and the appraisal of new programs or new ways of delivering and/or 
funding services. 
 
CHERE’s teaching includes introducing clinicians, health services managers, public health 
professionals and others to health economic principles.  Training programs aim to develop 
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Objective: The development of new genetic technology brings with it responsibility for 
evaluating the effectiveness and efficiency of testing programs, including gaining an 
understanding of the value of information.  This study examined the factors individuals took 
into account when making decisions about having a genetic test for Tay Sachs Disease. 
Participants, design and setting: Fifteen people participated in an in-depth interview as they 
attended a clinic for genetic testing. A thematic analysis of the data was undertaken. 
Results: Participants were most influenced to have testing by personal factors: e.g. ethnic 
background and desire to have children.  Disease characteristics were also important. The 
results informed the development of a Stated Preference Discrete Choice (SPDCM) 
experiment.  
Conclusions: Participants were motivated to have testing by a need for reassurance and 
certainty.  Thus, information was an important outcome for them. The results of the SPDCM 
experiment indicate that participants valued information positively thus providing support for 
the findings of the qualitative research. 
Key words: qualitative research, decision making, value of information, reassurance, 
certainty.  Genetic testing for inherited conditions 





Genetic testing, like many forms of screening, produces information and not health outcomes 
per se, although the information may enable individuals to take action which will improve 
their health. Genetic testing to determine individuals’ and couples’ carrier status, and thence 
their risk of having children affected with specific autosomal recessive diseases, is already 
available. With the progression of the Human Genome Project, possibilities for the detection 
of such genetic mutations are increasing rapidly. The information on carrier status will be 
translated into health outcomes through couples’ decisions to have or not have children; so the 
information is qualitatively different to other risk factors. Carrier status may bring with it 
feelings of guilt or blame (1). Knowing both partners are not carriers may bring feelings of 
relief and reassurance to proceed with pregnancies. Hence understanding the value of 
information to individuals being tested is important to understanding the value of testing. 
 
There are some circumstances in which information is likely to result in improved health 
outcomes. First, if the possession of a genetic mutation is associated with certainty (100% 
probability) with the development of a disorder for which there is an effective intervention, 
the best case scenario is that the disorder can be prevented or successfully treated. Second, if 
the possession of a genetic mutation is associated with certainty (100% probability) with the 
development of a disorder but there is no effective intervention available, prenatal testing can 
inform reproductive decisions which may lead to improved health outcomes at the population 
level. However, an individual who discovers that she or he has the genetic abnormality would 
not experience any health gain. 
 
Third, if the possession of a genetic mutation increases the likelihood (ie the risk) of 
developing a disorder and there is an effective intervention, some but not all those tested will Haas, Hall & De Abreu Lourenco 
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experienced improvements in health outcomes. Finally, if the risk of developing the disorder 
is increased but there is no effective intervention, there is no possibility of health gains (5). 
   
However, the decision to be tested is not just the result of an appraisal of the value of 
information. People agree to testing without having considered the implications of the results 
(2). Particularly during pregnancy, individuals may agree to testing without realising they 
have made a conscious choice (3). There is social pressure for parents to accept testing as part 
of being good parents (4).  
 
Individuals tested for carrier status prior to conception may use the information in different 
way: they may select a non-carrier partner, to avoid pregnancy with a carrier partner or to 
make decisions about pre-natal testing. A decision not to reproduce the abnormal gene will 
result in a decrease in the incidence of the disorder and an increase in population health 
outcomes. However, some carrier individuals may proceed with pregnancies knowing that 
there is a risk that the disorder will be transmitted to the foetus. In this case, there is no 
change to health outcomes although the parent/s have made a more informed decision (5).  
 
The decisions faced by individuals or couples are made more complex by variation in the 
severity of disorders, the age of onset and the type and amount of interventions used for 
monitoring or treatment. Thus, understanding how and why people decide to be tested is 
important to design effective and sensitive testing programs. Increasingly, new programs are 
being subject to economic evaluation, and have to be shown to be efficient as well. The usual 
approach to the economic appraisal of pre-pregnancy and pre-natal testing programs has been 
in terms of the cost per case of disease prevented (5); but this does not take into account the 
value of information and hence may not be a valid estimate of the benefits or consequences of  Genetic testing for inherited conditions 
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testing.  An alternative to cost effectiveness analysis which has been suggested is stated 
preference discrete choice modelling (6). This alternative requires the analyst to propose the 
features or attributes which will influence the individual’s decision, in this case the decision 
to be tested or not. 
 
This approach is relatively new in its application in health program evaluation. In most 
studies, the process by which the attributes were developed is not described. Yet the 
appropriate selection of the attributes is essential to the validity of the model. Further, the 
approach requires the collection of survey data. The questions and choices actually posed to 
respondents need to be phrased in language that they understand. 
 
Therefore,  an  important  step  in  designing  and  framing  such  evaluations  is  gaining  an 
understanding of the experiences of individuals who make decisions about participating in 
testing.  Qualitative  research  is  particularly  suited  to  exploratory  assessments  where  the 
objective is to understand why people behave as they do. Its techniques of data collection and 
analysis aim to elicit the meanings people apply to events and situations occurring in their 
lives and to provide insights into the beliefs and attitudes underlying their behaviour (7).  
Thus  it  provides  a  useful  first  step  in  identifying  the  appropriate  outcomes  for  economic 
evaluation. 
 
This discussion paper reports the results of qualitative research undertaken with a sample of 
people attending a Sydney hospital for genetic testing. The aims of the research were to: 
￿  explore the factors which influenced participants’ decisions to undergo genetic testing and 
￿  assess the benefits, risks and burdens of any decision 
 Haas, Hall & De Abreu Lourenco 
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3. BACKGROUND 
 
Participants attended the Wolper Jewish hospital (Sydney, NSW) intending to be tested for 
Tay-Sachs Disease (TSD).  However, the genetics testing program operating at the hospital 
also offers people the opportunity to be tested for three other inherited conditions: cystic 
fibrosis (CF); Canavan disease and Fanconi anaemia.  Individuals or couples can choose to 
have one test or any combination of the four tests available.  They can also choose to be tested 
and to receive their results as an individual or as a couple.  While those who receive their 
individual results learn their own carrier status, those who choose the couple option do not 
receive individual results, but learn their status as a couple.  Thus, if both are non-carriers or if 
one person only is a carrier, the couple will be told that, as a couple, they are unlikely to have 
a child with the condition/s they have been tested for.  Only when both members of a couple 
are carriers will they be told that there is a one-in-four chance that a pregnancy will result in 
the birth of an affected child. 
 
TSD is an autosomal recessive neurodegenerative disease, characterised by an accumulation 
of gangliosides throughout the body, resulting in progressive neurological dysfunction and 
death (8). Infants born with TSD usually die between the ages of three and five.  Adolescent- 
or adult-onset TSD are less severe forms of the disease and do not always result in death.  
TSD is most prevalent in the Jewish Ashkenazi population (Jewish individuals of Central and 
Eastern European descent).  Such individuals have a 1 in 25 chance of being carriers of TSD 
compared to a 1 in 250 chance for non-Ashkenazi Jewish people and the general population 
(9)). 
CF  is  also  an  autosomal  recessive  disorder.    It  affects  multiple  organs  and  varies  in  the 
severity with which it is manifested in individuals, but is usually fatal by age 30 (10).  The  Genetic testing for inherited conditions 
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disease  is  characterised  by  repeated  respiratory  infections,  pulmonary  obstruction  and 
pancreatic  insufficiency,  resulting  in  increasing  and  often  prolonged  periods  of  severe 
handicap.  Thus, CF is likely to have a measurable impact on an individual’s quality as well 
as length of life and result in comparatively high consumption of health care services and 
products.  Carrier rates for CF vary between 1 in 25 and 1 in 30 (11). 
 
Canavan  disease  is  similar  in  its  manifestation  to  TSD.    It  is  an  autosomal  recessive 
neurogenerative  condition  which  is  more  common  among  people  of  Ashkenazi  Jewish 
descent, who have a 1in 40 chance of being a carrier, compared to a 1 in 400 chance for the 
general population. 
 
Fanconi anaemia is an autosomal recessive disorder characterised by severe anaemia, immune 
system failure and malformations of other body systems including the skin and bones.  It is 
not restricted to any particular ethnic or regional group.  The carrier rate in the population is 1 
in 500. Haas, Hall & De Abreu Lourenco 
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4. METHODS  
 
People attending the Wolper Jewish Hospital for genetic testing for TSD were asked by the 
genetic counsellor administering the test(s) whether they would be willing to participate in a 
short face-to-face interview about the factors that influenced their decision to have genetic 
testing.  A list of the questions (including prompts) used as the basis for the interview are 
shown in Appendix One. Testing is offered once a month at the hospital and all people who 
attended between November 1999 and March 2000 were approached to participate.  Of the 22 
people attending during this time, 15 agreed.  The reasons for non-participation were 
overwhelmingly time-related.  Fifteen people were interviewed; four couples and seven 
individuals (all women).  It should be noted that the seven individuals were all members of 
couples who had made a decision not to be tested as a couple. All couples who agreed to be 
interviewed were interviewed together.  
 
All interviews were transcribed and a thematic analysis was carried out (12).  The analysis 
was undertaken by the first author (MH) using the following steps: 
1.  After listening to the tapes and reading the transcriptions a list of issues raised by the 
respondents was produced; 
2.  The transcriptions were searched for “significant statements” (i.e. statements made by 
respondents which were directly relevant to the issues, including opinions, preferences 
and assumptions); 
3.  The statements were interpreted.  This can also be described as moving from what was 
said to what was meant; 
4.  The meanings were clustered into broader categories called themes;  Genetic testing for inherited conditions 
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5.  Using the themes as a framework, the “results” were described in detail, using direct 
quotes from the interviews to illustrate the points being made. 
 
The research was undertaken with the approval of the University of Sydney Human Ethics 
Committee.  
 Haas, Hall & De Abreu Lourenco 
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5. RESULTS 
In this section, the themes emerging from participants’ descriptions of decision making 
related to genetic testing are reported.  Each theme is illustrated by one or more quotes.  After 
each quote the participant is identified as either female (F) or male (M) and by whether she/he 
was part of a couple (C) or attended for testing alone (S).  
 
TSD is a particular problem for Jewish people 
Almost all participants had known about TSD for a long time, including its effect on children 
and families and the fact that a genetic test is available. A few were able to describe being 
taught about it at school, others claimed that it was knowledge passed on to them by their 
family.  Two responses illustrate this: 
I have known about it for a very long time.  Probably since we were kids (M,C). 
I’ve known about it for a long time, I think initially through my studies (M,S). 
 
Despite their good general understanding of TSD, all participants appreciated the detailed 
information supplied by the testing program about the diseases being tested for and the tests 
on offer. This was described by participants as information which did not affect the decision 
they had made (i.e. to have the test) but which made the process of having the test easier.  
That is, it assisted their decisions about whether to have the test as an individual, as 
individuals within a couple separately or as a couple together and of how they would receive 
the results. In this way, such information may have enhanced their perception that they were 
doing the right thing in having a test.  Some typical responses were: 
It [the information] didn’t influence my decision [to be tested] but it made the process easier.  It was 
good to have someone who knew a bit about it to have a talk with them on the phone (M, C). 
We’d made our decision [to have the test] but we wanted to hear what it was about as well (F, C). 
  Genetic testing for inherited conditions 
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We always intended to be tested 
Many participants claimed that their decision to be tested was a long-standing one.  That is, 
they had always known that they would have the test – it was just a matter of deciding when.  
Some people described some personal knowledge or family link with TSD (a relative born 
with TSD or a friend of the family having a child with TSD) as being the catalyst for their 
(and sometime their family’s) expectations that they would be tested.  However, others 
described the decision to get married or to have children as the (short-term) trigger which 
prompted them to investigate the test.  The following responses illustrate these factors in the 
decision making process: 
I have a history of one case [of TSD] in my family plus my sister and my cousin had the test (M,C). 
It’s sort of an expectation really, getting married and having the test (F,S). 
It’s [having the test] been on my mind, and we’re getting married in five weeks and just decided to have 
the test (M,C).  
We wouldn’t have the test if we weren’t thinking about having a baby (F,C). 
 
Whenever the decision was made, it was often made on the advice of others – parents 
(usually mothers), prospective spouses, friends or doctors were mentioned: 
Because they’re concerned as a family, my parents and her [fiancee’s] parents said have you had your 
Tay-Sach’s test (M,C). 
We have got some friends who have had the test.  It’s pretty common among our peer group (M,C). 
There were probably two or three couples I knew who said they were going to do it [have the test].  
After that, it was natural [to consider having the test] (F,C). 
Well, my gynaecologist [advised her to have the test].  I actually called her to tell her I was pregnant 
and she called me and told me to go for a Tay-Sach’s test (F,S). 
 Haas, Hall & De Abreu Lourenco 
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Many people insisted that the decision making process they undertook was neither 
complicated nor drawn out. Their attitude was “the test is available, it seems to apply to me, 
why not have it?” 
I didn’t think [about getting tested], I just made a decision to get tested because I was worried about the 
implications of the disease [TSD] (M,C). 
It was a simple decision that we were going to do it (F,C). 
 
It’s better to know the risks 
Almost all the participants cited the desire to be relieved of worry about their risk of passing 
TSD to their children as the major reason for having the test. 
Because we want to have a baby so before we fall pregnant we want to know if we are at risk (M,C). 
It’s part of becoming pregnant, first of all being tested (F,S). 
It’s [the benefits of the test] reassurance I’ve done everything I can to prevent it [TSD] (F,C). 
Whatever you can do to neutralise those concerns [about having an affected child] gives you more 
peace of mind (M,C). 
The results will give me peace of mind hopefully.  It you’re going to have kids you might as well check 
it out (M,C). 
 
A related aspect which was also mentioned was the desire to know their status (and thus be 
certain of it and hence their risk of passing the disease on). 
We’re very health conscious and very grateful for the medical technologies that are available and we 
plan to take full advantage of them to find out our status (F,C). 
 
A number of people described the test as one part of a process of elimination – this (and other 
tests) were their contribution to doing all they could to ensure the birth of a healthy child: 
It [the test] fitted in with my character of being cautious and doing the best things possible to have a 
healthy child (M,C). 
It’s a process of elimination.  You eliminate all the things that are likely to cause problems (M,C).  Genetic testing for inherited conditions 
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It will be an extra precaution I’ve taken and I don’t have to worry if I do have children (F,S). 
 
A few participants described how they would use the information from the test to make 
another set of decisions (i.e. to try to become pregnant or to have an amniocentesis). 
If you are going to be having further tests or about doing an amniocentesis you should be able to time 
things appropriately (F,C). 
If there is a positive [test] it means we can take whatever the steps are to make an informed choice 
about what the future holds (F,C). 
 
As they had come for testing, it is likely that all participants believed that the potential 
benefits of the test (i.e. increased certainty, peace of mind and the knowledge that they had 
done the right thing) outweighed any negative aspects. However, a few were able to cite 
factors which were or might be a barrier to having the test.  These included the fact that it 
involved having a blood test, knowledge that a negative result would not completely eliminate 
their chances of having a child with TSD, fear of the results and the cost of the test(s). 
I don’t really like having my blood taken, it is just a physical concern (F,S). 
Well [I’ll] never be sure [that I won’t have a child with TSD], I think [genetic counsellor] says they 
give you statistics like 99.5% sure (F,S). 
Naturally, you worry that you might test positive (F,C). 
It is quite expensive so I think the cost can be a barrier for people.  When we saw the cost it makes you 
think twice about having all four tests (F,C). 
 
A moral responsibility to prevent suffering 
Almost all participants mentioned the “horrific” nature of TSD and their desire not to put a 
child through such suffering or to bear the brunt of such suffering themselves as one of the 
reasons they had decided on testing.  Haas, Hall & De Abreu Lourenco 
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I think having a baby born into this world that’s going to go through any kind of pain and then die 
young -–I wouldn’t want to put a child through that (F,C). 
Knowing I could be the carrier of a disease which will render my child dead within two years – it’s a 
pretty frightening thought (M,C). 
 
A number of people also mentioned a feeling of responsibility to the wider community, and, 
in particular, their responsibility to do the right thing by the Jewish community. 
I think if you have a chance of preventing or decreasing the genetic disease in your local community, it 
should be tackled (M,C). 
It’s better for everyone in the Jewish community in the long run – maybe eventually find a cure (F,S). 
 
Consequences of testing 
While the consequences of any positive results were referred to by about half the participants, 
most were unwilling to discuss details of their decisions if they were to find out they that they 
were carriers of the TSD gene.  While one or two referred to pre-natal testing as the next 
logical step, others referred to the next steps as decisions they would only consider if they had 
to. 
[We would consider] having further tests or about doing an amniocentesis (F,C). 
It [a positive test] may not change the fact that we try and have a baby but it will mean that we can 
prepare ourselves better for the potential consequences (M,C). 
I suppose we’ll find out first if it was positive and then we will see what steps to take (F,C). 
If [wife] is positive as well, then it’ll be a real dilemma, what to do. A real dilemma (M,C). 
 
While many people had discussed having the test with family members, only a few 
considered that the results of their test would be important for family members.  This may 
have been because the discussions were likely to have been with older members of the family  Genetic testing for inherited conditions 
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(e.g parents) and they perceived that the results were applicable to younger members who 
were likely to have children.  
 
Some people stated that they would only pass on the results if they were positive i.e. that 
either individually or as a couple, they were carriers of the gene for TSD. 
I think if it came back that I was [a carrier], I think it will be useful for relatives to know and be tested 
(F,S). Haas, Hall & De Abreu Lourenco 
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6. DISCUSSION AND CONCLUSIONS 
 
It has been proposed that a number of factors are likely to influence individuals’ decisions to 
undergo genetic testing.  These include the characteristics of the disease (i.e. the age of onset, 
prognosis, severity), the characteristics of the test (e.g. level of discomfort, predictability) and 
personal characteristics (e.g. age, level of education).  The participants in this study were most 
influenced by personal factors such as their Jewish ancestry and desire to have children as 
well as by the characteristics of TSD as a fatal disease predominantly affecting infants.  The 
characteristics of the test were less important to participants.  Two or three people mentioned 
the distasteful nature of blood tests, but also denied that this characteristic had ultimately 
influenced their decision, although it may have delayed their having the test. Approximately 
the same number mentioned that they were aware that the test was not a perfect predictor of 
their chances of having an affected child, but, as with their dislike of blood tests, believed that 
the benefits of the test outweighed this negative aspect. 
 
Participants in this research were largely motivated to have genetic testing by a desire to 
eliminate some of the risk associated with having a child, that is, by their need for reassurance 
and certainty.  Thus the value of information was an important component of the decision to 
be tested.  Some also believed that the testing program could benefit the wider community of 
Jewish people, indicating that feelings of social responsibility and altruism were also 
important in their decision making.  Participants were more likely to be encouraged or 
expected to have the tests by members of their family and community than by health 
professionals.  
 
No test is 100% sensitive and specific. Couples where both partners are identified as carriers 
can still have unaffected children (3 in 4 chance); and two partners told they are not carriers  Genetic testing for inherited conditions 
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can still have rare mutations that will produce affected children. The extent to which the value 
of information is influenced by the certainty attached to that information is worth further 
investigation. 
 
Although the potentially negative aspects of testing, including the possibility of a positive test 
and cost were mentioned by a few participants, testing was widely regarded as beneficial.  
This result is not surprising as the sample of respondents was limited to people who had 
already decided to be tested.  People who had considered testing but decided against it and 
non-Jewish people may have a different perspective on the factors influencing their decisions 
about genetic testing.  Nonetheless, the study provides important insights into how the 
recipients of testing perceived the potential positive and negative consequences of the tests.  
 
As alluded to in the Introduction, the results of this study informed the design of a Stated 
Preference Discrete Choice experiment which aimed to elicit preferences for screening for 
Tay-Sachs disease and cystic fibrosis and to value benefits beyond carrier detection. The 
attributes chosen for the SPDCM survey included carrier risk, disease severity, proportion of 
other people tested, rate of false negatives, cost and doctor recommendation. The survey was 
completed by 471 adults in metropolitan Sydney (261 representatives of the general 
population and 210 Ashkenazi Jewish people).  
 
The results indicated that individuals were prepared to pay for testing, and to pay more for 
test results with a lower false negative rate, implying a positive value for information.  
Interestingly, individuals were more likely to be tested the more prevalent testing was in the 
community, counter to the idea of the economic rational self-interested decision-maker. 
Preferences were also sensitive to doctor’s recommendation and carrier risk, and were Haas, Hall & De Abreu Lourenco 
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affected by individuals’ stage of life.  In addition to providing evidence about uptake of 
screening for these particular conditions, the results inform more general models of 
participation in screening programs and add to understanding of the consumer’s utility 
function. Thus, they have both clinical and policy relevance in terms of showing the potential 
uptake of testing in response to alterations to the testing program (13).  
  Genetic testing for inherited conditions 
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8. APPENDIX ONE: 
Research Study into  
“How individuals make decisions about and assess the benefits 
 and burdens of genetic testing”. 
 
Questions for participants 
 
First of all, can you tell me how you found out about the test for Tay-Sachs disease? 
    What made you think that you might get tested? 
     
What were the sorts of things which helped (are helping) you make a decision about 
having a test? 
    (If had test) Were there any particular factors which influenced your decision? 
[for example, influence of family, friends, health professionals, probability of being at risk, 
disease characteristics, accuracy of test results] 
(If not had test) What sorts of things are you taking into account as you think about whether or 
not to have testing? [for example, influence of family, friends, health professionals, probability 
of being at risk, disease characteristics, accuracy of test results] 
 
(if already decided/tested) Could you describe the process you went through in thinking 
about whether or not to have the (genetic disorder) test?  
Took time to think things over? 
Gathered information about disease/mode of inheritance/test (e.g. read books, pamphlets, the 
Internet etc.)? 
Sought opinions of others (experts/family/others) 
Discussed the implications of the results? 
 
What was/were the most important factor/s which influenced your decision to have the 
test? What was done to help you in making the decision? Could anything else have been 
done? 
Did the way you were treated or the manner of the health professionals make any difference? How? 
 
Did you have any worries or concerns about having the test? 
  (If yes) why/how are the worries/concerns not as important as the benefits of the test? 
(If yes) what, if anything, could have (or did) relieved any worries/concerns you have/had? 
 




Information and knowledge 
Effect on family members 
 





Effect on family members 
 
What have (will) the test results told (tell) you? 
How have (will) the results been (be) useful to you?  Genetic testing for inherited conditions 
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Have (Do you think) the results been (will be) useful to other members of your family?  
How? 
 
(if undecided about being tested) What sort of process are you going through in making 
the decision? 
    Gathering information 
Getting advice/opinions 
Discussion of the implications of being tested 
Weighing up the pros and cons of being tested 
 
Do you have any worries or concerns about the test or the results you might receive? 
  (If yes) why/how are the worries/concerns not as important as the benefits of the test? 
(If yes) what, if anything, could have (or did) relieved any worries/concerns you have/had? 
 
 
Is there anything else you want to tell me about making these decisions? 
Thank you very much for participating in this study. 